↓ Skip to main content

Cochrane Database of Systematic Reviews

New generation antipsychotics for first episode schizophrenia

Overview of attention for article published in Cochrane database of systematic reviews, October 2003
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

policy
1 policy source
twitter
8 tweeters
weibo
1 weibo user
facebook
1 Facebook page

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
139 Mendeley
Title
New generation antipsychotics for first episode schizophrenia
Published in
Cochrane database of systematic reviews, October 2003
DOI 10.1002/14651858.cd004410
Pubmed ID
Authors

Johannes Hamann, Werner Kissling, Stefan Leucht, Christine Rummel-Kluge

Abstract

The new generation antipsychotics are associated with a lower risk of adverse effects compared with drugs such as haloperidol. Many treatment guidelines recommend the use of new generation ('atypical') antipsychotic drugs for people with a first episode of schizophrenia.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 139 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 1 <1%
United States 1 <1%
Canada 1 <1%
Unknown 136 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 14%
Student > Master 19 14%
Student > Ph. D. Student 15 11%
Other 13 9%
Student > Bachelor 12 9%
Other 37 27%
Unknown 24 17%
Readers by discipline Count As %
Medicine and Dentistry 49 35%
Psychology 26 19%
Nursing and Health Professions 9 6%
Pharmacology, Toxicology and Pharmaceutical Science 5 4%
Social Sciences 4 3%
Other 10 7%
Unknown 36 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2021.
All research outputs
#3,403,302
of 21,347,849 outputs
Outputs from Cochrane database of systematic reviews
#5,924
of 12,071 outputs
Outputs of similar age
#30,130
of 185,602 outputs
Outputs of similar age from Cochrane database of systematic reviews
#43
of 102 outputs
Altmetric has tracked 21,347,849 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,071 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 29.0. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 185,602 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.